Straits Times Index
3,280.10 -7.65 (-0.23%) Nikkei
37,934.76 +306.28 (+0.81%) Hang Seng
17,651.15 +366.61 (+2.12%) FTSE 100
8,139.83 +60.97 (+0.75%) Bitcoin USD
62,939.11 -1,536.68 (-2.38%) CMC Crypto 200
1,304.48 -92.06 (-6.59%)
Augmedix, Inc. (AUGX)
After hours:
| Previous close | 2.7900 |
| Open | 2.7800 |
| Bid | 2.8400 x 200 |
| Ask | 2.8900 x 200 |
| Day's range | 2.7500 - 2.8700 |
| 52-week range | 2.6100 - 6.2500 |
| Volume | |
| Avg. volume | 368,826 |
| Market cap | 138.908M |
| Beta (5Y monthly) | -0.13 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.4400 |
| Earnings date | 25 Mar 2024 - 29 Mar 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 6.07 |
GlobeNewswireAugmedix Awarded on Newsweek’s World’s Best Digital Health Companies 2024 List
SAN FRANCISCO, April 25, 2024 (GLOBE NEWSWIRE) -- Augmedix (Nasdaq: AUGX), a leader in ambient AI medical documentation and data solutions, has been named on Newsweek’s list of The World’s Best Digital Health Companies 2024. This prestigious award was presented by Newsweek and Statista Inc., the world-leading statistics portal and industry ranking provider. The list of awardees was unveiled on April 24th, 2024, and is available on the Newsweek website. Augmedix's inclusion highlights its commitm
- GlobeNewswire
Augmedix Launches Industry’s First Fully-Automated, GenAI-Powered, Medical Documentation Product for Emergency Departments
Following incubation with HCA Healthcare EDs, Augmedix announces the general availability of Augmedix Go in emergency departmentsSAN FRANCISCO, April 24, 2024 (GLOBE NEWSWIRE) -- Augmedix (Nasdaq: AUGX), a leader in ambient AI medical documentation and data solutions, today announced the general availability of Augmedix Go for emergency departments (EDs), marking the launch of the industry’s first fully-automated, generative AI (GenAI) powered medical documentation product for EDs across the cou
GuruFocus.comInsider Sell: Augmedix Inc's (AUGX) Chief Strategy Officer Ian Shakil Sells 92,787 Shares
On April 11, 2024, Ian Shakil, Chief Strategy Officer of Augmedix Inc (NASDAQ:AUGX), sold 92,787 shares of the company.
